Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1236802 | 0.90 | CRHR1 (0.63) | CRHR1MAPT | |
| SCHEMBL1237773 | 0.89 | CRHR1 (0.65) | CRHR1MAPT | |
| SCHEMBL7038558 | 0.84 | NPY1R (0.59) | CRHR1MAPT | |
| SCHEMBL14350135 | 0.78 | TSHR (0.55) | CRHR1MAPT | |
| SCHEMBL14491021 | 0.77 | CRHR1 (0.52) | CRHR1MAPT | |
| SCHEMBL1868622 | 0.76 | CRHR1 (0.70) | CRHR1MAPT | |
| SCHEMBL12889148 | 0.76 | CRHR1 (0.77) | CRHR1 | |
| SCHEMBL12888871 | 0.75 | CRHR1 (0.63) | CRHR1 | |
| SCHEMBL1867368 | 0.74 | CRHR1 (0.68) | CRHR1MAPT | |
| SCHEMBL5729669 | 0.74 | CRHR1 (0.65) | CRHR1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1802627-B1 | PYRAZOLO (1,5-ALPHA) PYRIMIDINYL DERIVATIVES USEFUL AS CORTICOTROPIN-RELEASING FACTOR (CRF) RECEPTOR ANTAGONISTS | SMITHKLINE BEECHAM CORK LTD (IE) | 2012-08-29 | — | — | EP | disclosed |
| US-7879862-B2 | Central nervous system disorders; psychological disorders; anxiolytic agents; irritable bowel syndrome; antidepressants | SMITHKLINE BEECHAM (CORK) LIMITED (IE) | 2011-02-01 | — | — | US | disclosed |
| US-20080194589-A1 | Pyrazolo[1,5-Alpha]Pyrimidinyl Derivatives Useful as Corticotropin-Releasing Factor (Crf) Receptor Antagonists | NEUROCRINE BIOSCIENCES, INC. (US) | 2008-08-14 | — | — | US | disclosed |
| EP-1802627-A1 | PYRAZOLO (1,5-ALPHA) PYRIMIDINYL DERIVATIVES USEFUL AS CORTICOTROPIN-RELEASING FACTOR (CRF) RECEPTOR ANTAGONISTS | SB Pharmco Puerto Rico Inc. (PR) | 2007-07-04 | — | — | EP | disclosed |
| WO-2006044958-A1 | PYRAZOLO [1,5-ALPHA] PYRIMIDINYL DERIVATIVES USEFUL AS CORTICOTROPIN-RELEASING FACTOR (CRF) RECEPTOR ANTAGONISTS | SB PHARMCO PUERTO RICO INC. (PR) | 2006-04-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080194589-A1 | Pyrazolo[1,5-Alpha]Pyrimidinyl Derivatives Useful as Corticotropin-Releasing Factor (Crf) Receptor Antagonists | CRHR1, CRH, CRHR2 | CRHR1 1/4885MAPT 4668/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.